MAIA Biotechnology, Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
MAIA$1.09+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development expenses | $10,009,229 | $11,112,257 |
| General and administrative expenses | 6,947,981 | 9,070,124 |
| Total operating expenses | 16,957,210 | 20,182,381 |
| Loss from operations | (16,957,210) | (20,182,381) |
| Other income (expense): | ||
| Interest expense | (57) | (6,863) |
| Interest income | 318,367 | 34,490 |
| Australian research and development incentives | 79,954 | 176,719 |
| Change in fair value of warrant liability | (6,682,758) | 205,130 |
| Loss on fair value of warrants over proceeds | (12,952) | — |
| Other income (expense) net: | (6,297,446) | 409,476 |
| Net loss | $(23,254,656) | $(19,772,905) |
| Net loss per share | ||
| Basic and diluted | $(1.05) | $(1.49) |
| Weighted average common shares outstanding basic and diluted | 22,197,517 | 13,261,572 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.